UNITY Biotechnology, Inc. Appoints Camille Landis as Senior Vice President of Corporate Development
UNITY Biotechnology, Inc. Appoints Camille Landis as Senior Vice President of Corporate Development
May 14, 2018
“Camille brings significant experience in building and leading corporate development organizations,” said Keith Leonard, chairman and chief executive officer of UNITY. “UNITY will be evaluating opportunities to extend our reach and to bring innovative medicines that can change the trajectory of aging and extend human healthspan, and we’re pleased to have Camille onboard to lead this process.”
Ms. Landis most recently served as chief business officer at Eidos Therapeutics, where she oversaw the company's corporate development and financing activities. Prior to Eidos, she was vice president of corporate development at Relypsa, where she was responsible for building and leading corporate development, alliance management and strategic planning. She led the sale process of Relypsa to Galencia for $1.5 billion and supported the company's IPO and financing activities, which raised over $475 million. She also led Relypsa's global partnering effort that resulted in a $165 million licensing agreement with Vifor Fresenius Medical Renal Pharma and a co-detailing agreement with
About
Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements related to our potential to bring multiple medicines to market to impact aging and extend human healthspan. Such forward-looking statements involve substantial risks and uncertainties that could cause UNITY’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including UNITY’s early stage of development and its understanding of senescence biology, the clinical trial enrollment process, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, UNITY’s ability to successfully protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations and the availability or commercial potential of UNITY’s product candidates. UNITY undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s recently filed Registration Statement on Form S-1 and any subsequent current and periodic reports filed with the
InvestorsUNITY Biotechnology, Inc. Bob Goeltz Chief Financial Officer 1-650-525-4980 bob.goeltz@unitybiotechnology.com MediaCanale Communications Jason Spark 1-619-849-6005 jason@canalecomm.com
Source: Unity Biotechnology, Inc.